Evidence map›Paper›PMID 41846299›Full record

ArticleBritish journal of haematology2026

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.

Jorge N Ruiz Lopez, Lipei Shao, Debbie Jiang, Lawrence S Bailey, Thejaswi Bikkani, Aaron Boothby, Donald C Moore, Irina Murakhovskaya, Caroline I Piatek, Mauricio Pineda-Roman and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jorge N Ruiz LopezUniversity of Washington, Seattle, WA, USA.ORCID https://orcid.org/0000-0002-0546-1127
Lipei ShaoCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-3009-7096
Debbie JiangHematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-2978-3585
Lawrence S BaileyBloodWorks Northwest, Seattle, WA, USA.
Thejaswi BikkaniUniversity of Washington, Seattle, WA, USA.
Aaron BoothbyUniversity of Washington, Seattle, WA, USA.
Donald C MooreDepartment of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer, Concord, North Carolina, USA.
Irina MurakhovskayaDepartment of Hematology-Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, USA.
Caroline I PiatekJane Anne Nohl Division of Hematology, USC Norris Comprehensive Cancer Center, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-8628-8348
Mauricio Pineda-RomanDepartment of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer, Concord, North Carolina, USA.
Ping JinCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Jacqueline N PostonLarner College of Medicine, University of Vermont, Burlington, Vermont, USA.
Moritz StollaUniversity of Washington, Seattle, WA, USA.ORCID https://orcid.org/0000-0002-2866-1674
David F StroncekCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-5867-3265
Krystalyn E HudsonDepartment of Pathology and Cell Biology, Columbia University, New York, New York, USA.ORCID https://orcid.org/0000-0001-5663-9290
James B BusselDepartment of Pediatric Hematology and Oncology, Will Cornell Medical College, New York, New York, USA.ORCID https://orcid.org/0000-0002-2884-9247
Sandhya R PanchUniversity of Washington, Seattle, WA, USA.ORCID https://orcid.org/0000-0002-7814-9150

Funding

NIH Clinical CenterRigel Pharmaceuticals
6 · The paper itself

Abstract

Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction. In an eight-patient subset, migration inhibitory factor (MIF) levels, naïve (CD62L

Indexed as

Anemia, Hemolytic, AutoimmuneOxazinesPyridinesThrombocytopeniaAminopyridinesFemaleHumansMorpholinesPyrimidinesRetrospective StudiesTreatment OutcomeAminopyridinesfostamatinibMorpholinesOxazinesPyridinesPyrimidinesautoimmune haemolytic anaemiafostamatinibimmune cytopenias

Identifiers

PMID41846299
PMCPMC13176532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.